MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

CIK 0001823239 49 ready 8-Ks latest June 3, 2026, 8:31 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: auditor change (2)

Ready 8-Ks 49

Latest filing June 3, 2026, 8:31 AM ET

Top materiality 0.90

Event mix earnings ×19 · leadership ×12 · other_material ×10

Sentiment 11 pos · 13 neg · 25 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for MRVI

Highest-materiality recent filing

Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

August 11, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 2.05 item 5.02 item 9.01 ◈ Restructurings & Charges

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.

Read filing →

June 3, 2026, 8:31 AM ET debt materiality 0.65 positive item 1.01 item 1.02 item 2.03 item 7.01 item 9.01 ◈ Debt Financings ×2◈ Material Agreements ×2

Maravai LifeSciences refinances credit agreement, reduces debt by ~$93M and extends maturity to 2032

New $150M term loan and $30M revolver mature June 2032; proceeds plus $98.5M cash repaid $242.9M prior debt due Oct 2027.
May 29, 2026, 4:19 PM ET other material materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×3

Maravai shareholders elect three directors, ratify Deloitte & Touche, approve executive pay

Elected Bernd Brust (182.9M for), Gregory T. Lucier (179.5M for), Luke Marker (182.2M for) as directors for three-year terms.
May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Maravai LifeSciences Q1 revenue up 41% to $65.8M; raises full-year guidance

Q1 2026 revenue $65.8M, up 40.5% YoY; net loss improved to $(6.4)M from $(52.9)M.
February 25, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Maravai Q4 revenue $49.9M, net loss $63M; guides 2026 revenue $200-210M

Q4 revenue $49.9M, net loss $(63.0)M, positive Adj EBITDA $0.5M (non-GAAP).
November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Maravai Q3 revenue $41.6M, net loss $45.1M, Adj EBITDA -$10.8M

Revenue of $41.6 million, net loss of $45.1 million, and Adjusted EBITDA loss of $10.8 million for Q3 2025.
October 27, 2025, 7:59 PM ET leadership materiality 0.40 neutral item 5.02

Maravai LifeSciences reduces board from 11 to 8; three directors resign

Benjamin Daverman, Jessica Hopfield, and Murali Prahalad resigned from the Board effective Oct 21, 2025.
August 11, 2025, 7:59 PM ET earnings materiality 0.90 negative item 2.02 item 2.05 item 5.02 item 9.01 ◈ Restructurings & Charges

Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
July 18, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Maravai LifeSciences dismisses EY, appoints Deloitte; material weakness disclosed

EY dismissed as auditor; Deloitte appointed effective July 16, 2025 for FY 2025.
June 25, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 7.01 item 9.01

Maravai LifeSciences appoints Rajesh Asarpota as CFO effective June 30, 2025, succeeding Kevin Herde

Rajesh Asarpota appointed EVP and CFO effective June 30, 2025; Kevin Herde transitions to advisory role through Jan 31, 2026.
June 9, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai LifeSciences appoints Bernd Brust as CEO, succeeding William Martin

Bernd Brust named CEO and board member effective June 8, 2025; William Martin resigned as CEO and from board.
May 28, 2025, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Maravai shareholders elect 4 directors, ratify EY, approve say-on-pay at 2025 meeting

Elected Sean Cunningham, John DeFord, Jessica Hopfield, Murali Prahalad as directors for three-year terms; each received over 88% of votes cast.
May 12, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

Maravai Q1 revenue $46.9M (-27% YoY), net loss $(52.9)M, adj EBITDA $(10.5)M

Revenue $46.9M vs $64.2M in Q1 2024; net loss $(52.9)M includes $12.4M goodwill impairment.
March 20, 2025, 7:59 PM ET other material materiality 0.75 neutral item 7.01

Maravai LifeSciences guides 2025 revenue $185M-$205M; Q1 revenue $43M-$45M

Full-year 2025 revenue guidance $185M-$205M; Q1 2025 revenue $43M-$45M.
March 18, 2025, 7:59 PM ET other material materiality 0.85 negative item 2.02 item 4.02 item 9.01

Maravai restates Q2/Q3 2024 financials due to $3.9M revenue recognition error; Q4 revenue down 24%

Non-reliance on Q2 and Q3 2024 financials; restatement corrects $3.9M revenue timing error.
February 25, 2025, 6:59 PM ET other material materiality 0.75 negative item 2.02 item 7.01 item 9.01

Maravai postpones Q4/FY2024 earnings, cites material weakness in revenue recognition and potential goodwill impairment

Earnings release and call postponed; 10-K filing delayed until March 18, 2025.
January 8, 2025, 6:59 PM ET other material materiality 0.55 neutral item 2.02 item 5.02 item 9.01 ◈ executive_change

Maravai expects 2024 revenue near midpoint of $255M-$265M; President of Nucleic Acid Production departs

Preliminary unaudited 2024 revenue expected near midpoint of $255M-$265M guidance range.
December 18, 2024, 6:59 PM ET debt materiality 0.65 positive item 8.01

Maravai prepays $228M of term loan; remaining balance ~$300M

Voluntarily prepaid $228M aggregate principal of term loan using cash on hand.
December 5, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01

Maravai LifeSciences Chairman Carl Hull Retires; R. Andrew Eckert Appointed Chairman

Founder Carl Hull retires as Executive Chairman and resigns from Board, effective Dec 5, 2024; departure not related to any disagreement.
November 7, 2024, 6:59 PM ET earnings materiality 0.80 negative item 2.02 item 9.01

Maravai reports Q3 loss of $176M on $154.2M goodwill impairment; acquires Officinae Bio DNA/RNA business

Q3 revenue $65.2M (down 2.5% YoY); net loss $(176.0)M includes $154.2M goodwill impairment.
September 12, 2024, 7:59 PM ET debt materiality 0.50 neutral item 1.01 item 9.01

Maravai extends $167M revolver maturity by five years via credit amendment

Maravai entered Third Amendment on Sep 10, 2024 to extend $167M revolver maturity from Oct 2025 to five years later, subject to springing maturity tied to term loan (Oct 2027).
August 7, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance

Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.
July 29, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Maravai CEO Trey Martin appointed to Board of Directors, effective July 31, 2024

CEO William 'Trey' Martin III appointed as Class III director, effective July 31, 2024.
June 12, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 ◈ executive_change

Director Anat Ashkenazi to resign from Maravai board on July 31, 2024

Anat Ashkenazi notified Board of resignation effective July 31, 2024.
May 28, 2024, 7:59 PM ET other materiality 0.10 neutral item 5.07

Maravai shareholders elect directors, ratify auditor, approve executive compensation at 2024 annual meeting

Elected four director nominees: Benjamin Daverman, Susannah Gray, Carl Hull, Constantine Mihas to three-year terms.
May 8, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q1 revenue down 19% to $64.2M; net loss widens to $22.7M; FY guide reaffirmed

Quarterly revenue $64.2M, down 19% YoY; Nucleic Acid Production fell 25% to $46.0M.
February 22, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases ×4

Maravai Q4 revenue plunges 64% to $74.1M; net loss $110M; FY24 guidance $265-285M

Revenue $74.1M (down 64% YoY); net loss $110M vs net income $87.4M year ago.
November 7, 2023, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually

Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.
August 7, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases ×3

Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin

Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.
July 27, 2023, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai LifeSciences completes planned CEO succession; Martin becomes CEO, Hull Executive Chairman

William 'Trey' Martin, III named CEO effective July 27, 2023; previously President of Biologics Safety Testing segment.
July 20, 2023, 7:59 PM ET leadership materiality 0.45 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai LifeSciences announces director resignation and appointment of Dr. John DeFord to board

Robert B. Hance resigned from Board effective July 19, 2023; resignation unrelated to any disagreement with management.
May 22, 2023, 7:59 PM ET other materiality 0.10 neutral item 5.07 ◈ Shareholder Votes ×3

Maravai LifeSciences shareholders elect three Class III directors at 2023 annual meeting

Anat Ashkenazi, Gregory T. Lucier, and Luke Marker elected as Class III directors with over 183M votes each.
May 8, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q1 revenue $79M, down 68% YoY; net loss $1.3M vs prior net income $146.9M

Revenue $79.0M, -67.7% YoY; net loss $(1.3)M vs net income $146.9M in Q1 2022.
March 13, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×2

Maravai LifeSciences COO Brian Neel Resigns; Andrew Burch Named Successor

Brian Neel resigned as COO, Nucleic Acid Production, effective March 31, 2023.
March 10, 2023, 6:59 PM ET other material materiality 0.60 positive item 7.01

Maravai LifeSciences confirms no exposure to Silicon Valley Bank

Company has no cash deposits or securities at Silicon Valley Bank.
February 22, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01 ◈ Earnings Releases ×3

Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme

Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.
December 1, 2022, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Maravai settles noncompete lawsuit; Martin to become President, then CEO in July 2023

Trey Martin to serve as President of Biologics Safety Testing segment from Dec 5, 2022.
November 2, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Maravai Q3 revenue $191.3M, down 7% YoY; net income $99.7M; guidance updated

Q3 revenue $191.3M (-6.6% YoY); net income $99.7M vs $132.2M prior year.
October 19, 2022, 7:59 PM ET leadership materiality 0.80 negative item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

CEO Trey Martin placed on paid leave after court-ordered noncompete TRO; Carl Hull named interim CEO

Delaware Court of Chancery issued TRO preventing Martin from working for Maravai; pending preliminary injunction hearing later this year.
October 3, 2022, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

Maravai names Trey Martin CEO, co-founder Carl Hull becomes Executive Chairman

Martin appointed CEO effective Sept 30, 2022, succeeding Carl Hull who becomes Executive Chairman.
August 4, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Maravai Q2 revenue $242.7M (+11% YoY), net income $156.7M (+17%), Adj. EBITDA margin 78% record

Q2 revenue $242.7M (+11% YoY); net income $156.7M (+17%); Adj. EBITDA $188.5M (78% margin).
May 16, 2022, 7:59 PM ET other materiality 0.15 neutral item 5.07

Maravai shareholders elect directors, ratify auditor, back annual say-on-pay at 2022 meeting

Elected four Class II directors: Cunningham, Hance, Hopfield, Prahalad, each with >206M votes for.
May 5, 2022, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 9.01

Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance

Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).
February 23, 2022, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Maravai Q4 revenue $228M, up 132% YoY; net income $127M; 2022 guidance raised to $920-960M

Q4 revenue $228.4M (+132% YoY); net income $127.1M (+778% YoY).
January 28, 2022, 6:59 PM ET M&A materiality 0.80 positive item 7.01 item 9.01

Maravai acquires MyChem for $240M cash; expands ultra-pure nucleotides for mRNA therapeutics

Purchase price $240M cash at close plus contingent consideration based on future conditions.
January 20, 2022, 6:59 PM ET debt materiality 0.55 neutral item 1.01 item 9.01

Maravai amends credit agreement; replaces LIBOR with SOFR, reduces interest margins, and refinances $544M term loans.

Amendment replaces LIBOR with Term SOFR; interest margin on Term SOFR loans reduced to 3.00% from 3.75%-4.25%.
January 3, 2022, 6:59 PM ET other material materiality 0.40 neutral item 8.01 item 9.01

Maravai contributes $110M to Topco, forfeits units; voting power shifts to 51.5%/48.5%

Contributed $110M to Topco for 2,732,919 Common Units at $40.25/unit (50-day VWAP).
November 10, 2021, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 9.01

Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook

Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.
September 3, 2021, 7:59 PM ET other material materiality 0.50 neutral item 1.01 item 2.01 item 9.01

Maravai closes sale of Protein Detection segment; amends Pfizer/BioNTech supply pact

Closed sale of Vector Laboratories (Protein Detection) to Voyager Group/Thompson Street on Sept 2, 2021.
August 10, 2021, 7:59 PM ET earnings materiality 0.80 positive item 1.01 item 2.02 item 9.01

Maravai Q2 revenue up 364% to $217.8M, raises FY guidance to $745-770M; selling Vector for $124M

Q2 revenue $217.8M (+364% YoY); net income $134.3M vs $1.4M; Adj. EBITDA $164.7M vs $17.5M.